Cargando…
The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899104/ https://www.ncbi.nlm.nih.gov/pubmed/36751250 http://dx.doi.org/10.7759/cureus.33407 |
_version_ | 1784882568857911296 |
---|---|
author | Abu-Tineh, Mohammad Ali, Elrazi A Alshurafa, Awni Nashwan, Abdulqadir J Albsheer, Khalid Ahmed, Ashraf Hailan, Yousef Rozi, Waail Aljaloudi, Esraa Yassin, Mohamed A |
author_facet | Abu-Tineh, Mohammad Ali, Elrazi A Alshurafa, Awni Nashwan, Abdulqadir J Albsheer, Khalid Ahmed, Ashraf Hailan, Yousef Rozi, Waail Aljaloudi, Esraa Yassin, Mohamed A |
author_sort | Abu-Tineh, Mohammad |
collection | PubMed |
description | Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survival rate close to one when compared to the general population. Consequently, new perspectives on the safety of treatments have emerged, particularly in the context of their impact on fatherhood in men. According to the authors, this is the first study to examine the effect of TKIs on fatherhood in CML patients. Methods: A single-center, mixed-design study (retrospective data review and phone interviews) was conducted with CML male patients in the chronic or accelerated phase, evaluating the effect of imatinib, dasatinib, and nilotinib on their fatherhood, irrespective of whether they were administered as a first, second, or third line of treatment. Results: The study included interviews with 150 patients. Included were 27 patients. The average age was approximately 44.5 years. One hundred percent of the patients were in the chronic phase. The median age at first conception following TKI therapy was 36, and the median duration of TKI therapy was approximately seven years. The total number of offspring was 49; 98% were born at term and had a normal birth weight. No reports of stillbirths, fetal deaths, or congenital malformations were made. All the offspring grew and developed normally. No CML-related cancers were reported in any of the newborns. Conclusion: Around 98% of male CML patients receiving imatinib, dasatinib, or nilotinib did not experience a negative impact on their fatherhood or the health of their children. However, improved education for patients beginning treatment with TKIs addresses the potential psychological worry of having an unfavorable effect on their fertility or offspring, which may increase medication adherence. |
format | Online Article Text |
id | pubmed-9899104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-98991042023-02-06 The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study Abu-Tineh, Mohammad Ali, Elrazi A Alshurafa, Awni Nashwan, Abdulqadir J Albsheer, Khalid Ahmed, Ashraf Hailan, Yousef Rozi, Waail Aljaloudi, Esraa Yassin, Mohamed A Cureus Oncology Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survival rate close to one when compared to the general population. Consequently, new perspectives on the safety of treatments have emerged, particularly in the context of their impact on fatherhood in men. According to the authors, this is the first study to examine the effect of TKIs on fatherhood in CML patients. Methods: A single-center, mixed-design study (retrospective data review and phone interviews) was conducted with CML male patients in the chronic or accelerated phase, evaluating the effect of imatinib, dasatinib, and nilotinib on their fatherhood, irrespective of whether they were administered as a first, second, or third line of treatment. Results: The study included interviews with 150 patients. Included were 27 patients. The average age was approximately 44.5 years. One hundred percent of the patients were in the chronic phase. The median age at first conception following TKI therapy was 36, and the median duration of TKI therapy was approximately seven years. The total number of offspring was 49; 98% were born at term and had a normal birth weight. No reports of stillbirths, fetal deaths, or congenital malformations were made. All the offspring grew and developed normally. No CML-related cancers were reported in any of the newborns. Conclusion: Around 98% of male CML patients receiving imatinib, dasatinib, or nilotinib did not experience a negative impact on their fatherhood or the health of their children. However, improved education for patients beginning treatment with TKIs addresses the potential psychological worry of having an unfavorable effect on their fertility or offspring, which may increase medication adherence. Cureus 2023-01-05 /pmc/articles/PMC9899104/ /pubmed/36751250 http://dx.doi.org/10.7759/cureus.33407 Text en Copyright © 2023, Abu-Tineh et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Oncology Abu-Tineh, Mohammad Ali, Elrazi A Alshurafa, Awni Nashwan, Abdulqadir J Albsheer, Khalid Ahmed, Ashraf Hailan, Yousef Rozi, Waail Aljaloudi, Esraa Yassin, Mohamed A The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study |
title | The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study |
title_full | The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study |
title_fullStr | The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study |
title_full_unstemmed | The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study |
title_short | The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study |
title_sort | impact of tyrosine kinase inhibitors on fatherhood in patients with chronic myeloid leukemia: a mixed-method study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899104/ https://www.ncbi.nlm.nih.gov/pubmed/36751250 http://dx.doi.org/10.7759/cureus.33407 |
work_keys_str_mv | AT abutinehmohammad theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT alielrazia theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT alshurafaawni theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT nashwanabdulqadirj theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT albsheerkhalid theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT ahmedashraf theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT hailanyousef theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT roziwaail theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT aljaloudiesraa theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT yassinmohameda theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT abutinehmohammad impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT alielrazia impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT alshurafaawni impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT nashwanabdulqadirj impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT albsheerkhalid impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT ahmedashraf impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT hailanyousef impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT roziwaail impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT aljaloudiesraa impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy AT yassinmohameda impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy |